Avian influenza is an infection caused by avian (bird) influenza (flu) viruses. These influenza viruses occur naturally among birds. Wild birds worldwide carry the viruses in their intestines, but usually do not get sick from them. However, avian influenza is very contagious among birds and can make some domesticated birds, including chickens, ducks, and turkeys, very sick and kill them.
Seasonal flu vaccines may protect individuals not only against the strains of flu they contain but also against many additional types, according to a study published this week in mBio, the online open-access journal of the American Society for Microbiology.
A University of Adelaide-led project has developed a new test that can distinguish between birds that have been vaccinated against the H5N1 strain of avian influenza virus or "bird flu" with those that have been naturally infected.
A large, NIH-sponsored clinical trial of an experimental H7N9 avian influenza vaccine found an immune response that was believed to be protective in 59 percent of study participants who received two injections of the inactivated vaccine at the lowest dosage tested when mixed with an adjuvant – a component that boosts the body's immune response and enhances the effectiveness of inactivated influenza vaccines.
Two randomized trials in the October 8 issue of JAMA examine new vaccination strategies for the prevention and control of avian influenza, often referred to as "bird flu." This is a theme issue on infectious disease.
A study led by St. Jude Children's Research Hospital scientists found the avian influenza A H3N8 virus that killed harbor seals along the New England coast can spread through respiratory droplets and poses a threat to humans.
Cepheid announced today the release of Xpert® Flu/RSV XC, an on-demand molecular test for rapid, accurate and reliable determination of Flu A, Flu B, and differentiation of RSV infection.
WIRB-Copernicus Group, the world's largest provider of regulatory and ethical review services for clinical research, announced today that it has acquired Alliance Biosciences. Formerly a division of Richmond, VA-based Alliance Engineering, Alliance Biosciences was the leading biosafety and biosecurity consulting firm in the United States.
Allowing patients to choose which hospital they attend when suffering illness during a pandemic rather than assigning them to a specific healthcare facility is appealing to patients during such a crisis. However, such a patient-centric hospital capacity management is conventionally viewed as inefficient system-wide.
Janssen Pharmaceuticals, Inc.announced today that it has entered into an exclusive license agreement with Vertex Pharmaceuticals for the worldwide development, manufacturing and commercialization of VX-787, a novel medicine in Phase II development for the treatment of influenza A.
Led by Marius Gilbert - Interfaculty School of Bioengineering, Université libre de Bruxelles - an international researcher team maps the risk of H7N9 bird flu infection in markets across Asia. The identification of high risk areas should helping to restrict the spread of this new disease.
United Nations University will help pioneer a fresh trail in global health research, exploring links between the planet's health and human health at an institute in Kuala Lumpur generously supported by Malaysia.
A group of University of Washington scientists is seeking broad, versatile countermeasures effective against several different kinds of viruses and other pathogens. The investigators are part of a national push for faster responses to unexpected infectious agents.
Among the copious species of poultry in China, quail and chickens are the likely sources of infection of H7N9 influenza virus to humans, according to a paper published ahead of print in the Journal of Virology.
While many endemic infectious diseases of humans have been largely contained, new microbes continue to emerge to threaten human and animal health.
A new study reconstructing the evolutionary tree of flu viruses challenges conventional wisdom and solves some of the mysteries surrounding flu outbreaks of historical significance.
Since its first identification in Asia, highly pathogenic avian influenza-H5N1-has caused significant alarm in the scientific community. While the virus' primary target is birds-tens of millions have already died from it-it is capable of infecting mammals, including humans, causing serious illness and a frightening rate of mortality.
Scientists from China report in The Lancet on the world’s first confirmed case of human infection with a new avian influenza A H10N8 virus in a 73-year-old woman who died from the infection.
Vivaldi Biosciences Inc., a clinical-stage biotechnology company developing live attenuated influenza vaccines against seasonal and pandemic influenza, today announced that it has signed a Cooperative Research and Development Agreement with the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, to generate and evaluate in preclinical studies LAIV candidates against influenza A(H7N9).
The habit of Googling for an online diagnosis before visiting a GP can provide early warning of an infectious disease epidemic.
Meridian Bioscience, Inc. today announced that the company's TRU FLU assay received FDA clearance for an analytical sensitivity claim for the novel avian Influenza H7N9 strain, A/Anhui/1/2013. TRU FLU is a rapid immunoassay that detects influenza A and influenza B viruses in 15 minutes in human respiratory specimens.